Theraclion Sa

Theraclion Announces the Launch of a Capital Increase Through the Issuance of ABSA (Shares With Share Warrants Attached), With Preferential Subscription Rights for Existing Shareholders, for a Gross Amount of €6 Million, Secured by Subscription...

Theraclion Publishes Its 2025 Financial Results and Provides an Update on Its Outlook

Theraclion Delivers a Structuring Year in 2025 and Prepares to Scale up

Theraclion Announces Sonovein FDA Submission Following a Strong Year of Regulatory and Clinical Achievements

Theraclion Reports Major Recent Developments and Announces Its 2025 Half-Year Financial Results